Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization

American Journal of Cardiovascular Drugs

Volumn 3, Issue 5, 2003, Pages 381-386

  Ibbotson, Tim ^a   McGavin, Jane K ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIBODY; CD11B ANTIGEN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; LYMPHOCYTE RECEPTOR; PLACEBO; RETEPLASE; TENECTEPLASE; TIROFIBAN; VITRONECTIN RECEPTOR;

ARTICLE; BLEEDING; BODY WEIGHT; BOLUS INJECTION; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DEATH; DIABETES MELLITUS; DISEASE DURATION; DRUG COST; DRUG EFFICACY; DRUG INFUSION; DRUG RECEPTOR BINDING; ELECTIVE SURGERY; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LEUKOCYTE ADHERENCE; MORTALITY; PRIORITY JOURNAL; STENT; SURGICAL APPROACH; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0242467985     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303050-00011     Document Type: Article

References (37)

1. Foster RH, Wiseman LR. Abciximab: an updated review of its use in ischaemic heart disease. Drugs 1998 Oct; 56 (4): 629-65
2. Faulds D, Sorkin EM. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994; 48: 583-98
3. Centocor BV. ReoPro. Abciximab for intravenous administration. Prescribing information. Leiden: Centocor BV., 2001 May
4. Jain AC, Billie M, Haque R, et al. Platelet inhibition by abciximab, tirobiban or eptifibatide during percutaneous coronary interventions in patients of acute coronary syndromes: a comparative evaluation. J Investig Med 2001 Jan; 49: 121A
5. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999 Aug 15; 84 (4): 391-5
6. Neumann F-J, Hochholzer W, Pogatsa-Murray G, et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001 Apr; 37 (5): 1323-8
7. Dangas G, Marmur JD, King TE, et al. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J 1999 Jul; 138 (1 Pt 1): 49-54
8. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001 Jun 21; 344 (25): 1888-94
9. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999 Dec 11; 354 (9195): 2019-24
10. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. EPILOG Investigators. Circulation 1999 Apr 20; 99 (15): 1951-8
11. Cho L, Marso SP, Bhatt DL, et al. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. J Womens Health Gend Based Med 2000 Sep; 9 (7): 741-6
12. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. Circulation 1999 Dec 21; 100 (25): 2477-84
13. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001 Jun 21; 344 (25): 1895-903
14. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002 Mar 28; 346 (13): 957-66
15. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000 Aug 10; 343 (6): 385-91
16. Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 2002 Mar 16; 359 (9310): 920-5
17. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000 Mar 15; 35 (4): 915-21
18. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Lancet 2001 Aug 25; 358 (9282): 605-13
19. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001 Jun 16; 357 (9272): 1905-14
20. Antman EM, Giugliano RP, McCabe CH, et al. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 trial [abstract no. 842-1]. J Am Coll Cardiol 1998 Feb; 31: 191A
21. SPEED Investigators. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000 Jun 20; 101 (24): 2788-94
22. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001 Jun 15; 37 (8): 2059-65
23. Cho L, Bhatt DL, Wolski K, et al. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: pooled analysis from EPIC, EPILOG, and EPISTENT. Am Heart J 2001 Apr; 141 (4): 599-602
24. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000 Aug; 36 (2): 381-6
25. Roe MT, Gum PA, Booth JE, et al. Consistent and durable reduction in death and myocardial infarction with abciximab during coronary intervention in acute coronary syndromes and stable angina: a pooled analysis from EPIC, EPILOG, and EPISTENT. Circulation 1999 Nov 2; 100 Suppl.: 1-187 (plus oral presentation)
26. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000 Mar 15; 35 (4): 922-8
27. Brown DL, Fann CSJ, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001 Mar 1; 87 (5): 537-41
28. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999 Nov 16; 100 (20): 2045-8
29. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001 Jun 16; 357 (9272): 1915-24
30. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000 Jul; 36 (1): 75-83
31. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. ReoPro Readministration Registry Investigators. Circulation 2001 Aug 21; 104 (8): 870-5
32. Zwart-van Rijkom JEF, van Hout BA. Cost-efficacy in interventional cardiology; results from the EPISTENT study. Eur Heart J 2001 Aug; 22 (16): 1476-84
33. Lincoff AM, Mark DB, Tcheng JE, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. EPILOG Investigators. Circulation 2000 Dec 12; 102 (24): 2923-9
34. Lucore CL, Trask RV, Mishkel GJ, et al. Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital. Coron Artery Dis 2001 Mar; 12 (2): 135-42
35. Zwart-van Rijkom JEF, Klungel OH, Leufkens HGM, et al. Costs and effects of combining stenting and abciximab (ReoPro) in daily practice. Int J Cardiol 2001 Feb; 77 (2-3): 299-303
36. PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) trial. PRICE Investigators. Am Heart J 2001 Mar; 141: 402-9
37. Lorenzoni R, Mazzotta G, Gensini GF, et al. Economic evaluation of abciximab in the pre-treatment of patients undergoing percutaneous transluminal coronary angioplasty in the context of the Italian health-care system [in Italian]. G Ital Cardiol 1999; 29 (3): 269-76